secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001213900-24-099633
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals Announces Positive Topline Results from AD04 Pharmacokinetics Study for Alcohol Use Disorder
--------------------------------------------------------------------------------

- Study enrolled 30 healthy volunteers in two cohorts: Cohort 1 (n=6) evaluated PK variability; Cohort 2 (n=24) assessed relative bioavailability, dose proportionality, and food effect.
- Results showed AD04 0.33mg delivered lower ondansetron PK exposure than marketed 4mg tablet; exposure increased proportionally across 3-fold dose range; no food effect observed.
- Completion of the study satisfied an FDA requirement for the upcoming Phase 3 clinical trials of AD04 and supports 505(b)(2) regulatory pathway.
- Company plans to engage with FDA in Q4 2024 to discuss study design for Phase 3, aiming to enhance likelihood of success and advance partnership discussions.
- Continued excellent safety and tolerability findings consistent with extensive human use experience with ondansetron.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024099633/0001213900-24-099633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024099633/ea022169101-8k_adialpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-099633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer